7 / 25
Impact in prognosis of circulating tumor DNA
Mutant Allele Fraction (MAF) in
RAS
mutant
metastatic Colorectal Cancer (mCRC)
º
E. Elez1,2, C. Chianese3(*), E. Sanz-García1,2(*), E. Martinelli4, A. Noguerido1,2, F.M. Mancuso3, J. Grasselli1,5, G.
Caratù3, J. Matito3, C. Santos5, T. Macarulla1,2, G. Argilés1,2, J. Capdevila1,2, A. Garcia1,2, N. Mulet 1,2,5, M.
Martinez, G. Soler, F. Jones6, J. Tabernero1,2, F. Ciardello4, R., Salazar5(**), A. Vivancos3(**)
1-Department of Medical Oncology, Vall d’Hebron Institute of Oncology, Barcelona, Spain; 2-Department of Medical Oncology, Vall d’ Hebron
University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; 3-Cancer Genomics Group, Vall d’Hebron Institute of Oncology, Barcelona,
Spain; 4-Medical Oncology, Department of Clinical and Experimental Medicine “F. Magrassi,” Università della Campania “L. Vanvitelli,” Napoli 5-
Department of Medical Oncology, Catalan Institute of Oncology, Universitat de Barcelona, L´Hospitalet, Spain; 6- Sysmex Inostics, Illinois, United States.